Alkem Laboratories Ltd. (NSE: ALKEM), a major Indian pharmaceutical player, reported solid unaudited financial results for the third quarter ended December 31, 2025. Total revenue from operations grew 10.7% year-over-year (YoY) to Rs. 37,368 million, driven by robust international expansion.
The company also unveiled a binding term sheet for acquiring a majority stake in Switzerland-based Occlutech Holding AG, a global leader in minimally invasive cardiac implants, via subsidiary Alkem MedTech Pvt Ltd.
Q3 FY26 Financial Performance
Earnings before interest, tax, depreciation, and amortization (EBITDA) reached Rs. 8,280 million, up 9.0% YoY, with margins steady at 22.2% versus 22.5% in Q3 FY25. Profit before tax (after exceptional items) rose 6.9% to Rs. 7,812 million. Net profit after non-controlling interest increased 1.6% to Rs. 6,360 million.
An exceptional item of Rs. 528 million stemmed from the Indian government’s notification on four Labour Codes. Research and development expenses rose to Rs. 1,390 million (3.7% of revenue) from Rs. 1,312 million (3.9%) YoY, underscoring innovation focus.
According to IQVIA (SSA) data, Alkem grew 9.8% YoY, slightly trailing the Indian Pharmaceutical Market (IPM) at 10.9%. It outperformed in acute (8.6% vs. IPM 7.8%) and chronic segments (15.8% vs. IPM 15.6%).
Domestic Business Strength
India sales hit Rs. 24,959 million, up 5.5% YoY, comprising 67.2% of total revenue (down from 71.1%). Alkem outpaced IPM in six therapies: anti-infectives (~1.4x), VMN (~2.0x), pain (~1.4x), anti-diabetic (~1.2x), respiratory (~1.2x), and derma (~1.8x). This reflects resilient execution in a competitive market.
International Business Surge
International sales jumped 26.6% YoY to Rs. 12,157 million, accounting for 32.6% of total revenue. US sales grew 18.8% to Rs. 7,533 million (20.3% of total), while non-US sales soared 41.6% to Rs. 4,624 million (12.5% of total).
In the US, Alkem filed two Abbreviated New Drug Applications (ANDAs) and secured seven approvals during the quarter. As of December 31, 2025, it had filed 188 ANDAs, two New Drug Applications (NDAs), and one Biologics License Application (BLA), with 167 ANDA approvals (including 20 tentative).
Strategic Occlutech Acquisition
The proposed majority stake in Occlutech marks a pivotal medtech entry. As the third-largest global player in minimally invasive cardiac implants, Occlutech offers strong R&D, manufacturing, and presence in high-barrier markets.
Sandeep Singh, Managing Director, noted: “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become meaningful growth pillar for the company.”
Leadership Commentary
Dr. Vikas Gupta, CEO, remarked: “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”
Alkem’s balanced growth across domestic and export markets, coupled with medtech diversification, positions it for sustained momentum in FY26.